PACB
Price
$0.95
Change
-$0.03 (-3.06%)
Updated
May 22, 01:52 PM (EDT)
Capitalization
976.68M
69 days until earnings call
SKHHY
Price
$17.20
Change
-$0.02 (-0.12%)
Updated
May 21 closing price
Capitalization
11.02B
Interact to see
Advertisement

PACB vs SKHHY

Header iconPACB vs SKHHY Comparison
Open Charts PACB vs SKHHYBanner chart's image
Pacific Biosciences of California
Price$0.95
Change-$0.03 (-3.06%)
Volume$10.26K
Capitalization976.68M
Sonic Healthcare
Price$17.20
Change-$0.02 (-0.12%)
Volume$17.66K
Capitalization11.02B
PACB vs SKHHY Comparison Chart
Loading...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKHHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PACB vs. SKHHY commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PACB is a Hold and SKHHY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (PACB: $0.98 vs. SKHHY: $17.20)
Brand notoriety: PACB and SKHHY are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: PACB: 96% vs. SKHHY: 31%
Market capitalization -- PACB: $976.68M vs. SKHHY: $11.02B
PACB [@Medical Specialties] is valued at $976.68M. SKHHY’s [@Medical Specialties] market capitalization is $11.02B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PACB’s FA Score shows that 0 FA rating(s) are green whileSKHHY’s FA Score has 1 green FA rating(s).

  • PACB’s FA Score: 0 green, 5 red.
  • SKHHY’s FA Score: 1 green, 4 red.
According to our system of comparison, SKHHY is a better buy in the long-term than PACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PACB’s TA Score shows that 3 TA indicator(s) are bullish while SKHHY’s TA Score has 5 bullish TA indicator(s).

  • PACB’s TA Score: 3 bullish, 4 bearish.
  • SKHHY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SKHHY is a better buy in the short-term than PACB.

Price Growth

PACB (@Medical Specialties) experienced а -10.80% price change this week, while SKHHY (@Medical Specialties) price change was +2.14% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.59%. For the same industry, the average monthly price growth was +7.19%, and the average quarterly price growth was -0.08%.

Reported Earning Dates

PACB is expected to report earnings on Jul 30, 2025.

SKHHY is expected to report earnings on May 21, 2025.

Industries' Descriptions

@Medical Specialties (+0.59% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SKHHY($11B) has a higher market cap than PACB($977M). SKHHY YTD gains are higher at: 4.751 vs. PACB (-46.383). SKHHY has higher annual earnings (EBITDA): 2.19B vs. PACB (-277.28M). SKHHY has higher revenues than PACB: SKHHY (8.65B) vs PACB (201M).
PACBSKHHYPACB / SKHHY
Capitalization977M11B9%
EBITDA-277.28M2.19B-13%
Gain YTD-46.3834.751-976%
P/E RatioN/A16.45-
Revenue201M8.65B2%
Total Cash631MN/A-
Total Debt934MN/A-
FUNDAMENTALS RATINGS
PACB vs SKHHY: Fundamental Ratings
PACB
SKHHY
OUTLOOK RATING
1..100
5421
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
10078
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9154
P/E GROWTH RATING
1..100
7348
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SKHHY's Valuation (2) in the null industry is significantly better than the same rating for PACB (100) in the Biotechnology industry. This means that SKHHY’s stock grew significantly faster than PACB’s over the last 12 months.

SKHHY's Profit vs Risk Rating (78) in the null industry is in the same range as PACB (100) in the Biotechnology industry. This means that SKHHY’s stock grew similarly to PACB’s over the last 12 months.

SKHHY's SMR Rating (100) in the null industry is in the same range as PACB (100) in the Biotechnology industry. This means that SKHHY’s stock grew similarly to PACB’s over the last 12 months.

SKHHY's Price Growth Rating (54) in the null industry is somewhat better than the same rating for PACB (91) in the Biotechnology industry. This means that SKHHY’s stock grew somewhat faster than PACB’s over the last 12 months.

SKHHY's P/E Growth Rating (48) in the null industry is in the same range as PACB (73) in the Biotechnology industry. This means that SKHHY’s stock grew similarly to PACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PACBSKHHY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 15 days ago
86%
Bullish Trend 4 days ago
68%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 2 days ago
69%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
75%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKHHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PJGZX21.37N/A
N/A
PGIM Jennison Focused Value Z
PRCOX59.03N/A
N/A
T. Rowe Price U.S. Equity Research
DGLYX21.10N/A
N/A
BNY Mellon Global Stock - Y
PEGEX20.64N/A
N/A
PGIM Jennison Mid-Cap Growth R2
EIPTX13.63N/A
N/A
UBS Engage For Impact P2

SKHHY and

Correlation & Price change

A.I.dvisor tells us that SKHHY and CHEOY have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SKHHY and CHEOY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKHHY
1D Price
Change %
SKHHY100%
-0.12%
CHEOY - SKHHY
28%
Poorly correlated
-1.85%
ILMN - SKHHY
27%
Poorly correlated
-5.75%
SAUHY - SKHHY
26%
Poorly correlated
-0.11%
PACB - SKHHY
24%
Poorly correlated
-3.80%
LAB - SKHHY
23%
Poorly correlated
-0.95%
More